At a glance
ClinicalIndex Comparison RecordPhase 2Active· 50 enrolled
Drug / intervention
ZG005 for Injectionbiological
Likely dose
ZG005 for Injection 20 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of ZG005 in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating ZG005 for Injection for Advanced Solid Tumor. Active but no longer recruiting, targeting 50 participants across 1 site.
Detailed Summary
This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2Active
20262027
First PostedApr 2025
Enrollment StartJun 2025
TodayJul 2026
Primary CompletionMay 2027
Study CompletionJun 2027
First PostedApr 15, 2025
Enrollment StartJun 13, 2025
Primary CompletionMay 1, 2027
Study CompletionJun 1, 2027
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 1.2 years agoPrimary completion in 10 months
Interventions
ZG005 for Injectionbiological
Recommended Phase 2 Dose (RP2D) of ZG005(20 mg/kg), intravenous infusion, once every 3 weeks.